International Sourcing of Specialty Medications: A Real Opportunity, Not a Shortcut

Most employer-sponsored international sourcing programs focus on a limited list of expensive medications used to treat chronic conditions.

Once an eligible employee is identified, the program coordinates with the employee, prescribing physician, and international pharmacy. The medication is usually shipped directly to the member, often at no cost.

The employer covers the medication and administrative fees, but the total cost is often much lower than traditional pharmacy benefit expenses.

This approach is appealing because employees can continue treatment — often without out-of-pocket costs — and the plan may avoid large domestic claims. However, price differences are only the starting point for analysis.

A common mistake is assuming that all medications purchased internationally are imported through authorized federal pathways.

The FDA's current Section 804 importation framework is primarily designed for authorized state and tribal programs importing eligible prescription drugs from Canada. It includes extensive requirements for supply chain integrity, testing, relabeling, adverse event reporting, and recalls. The program also excludes several important categories — biologic products, infused medications, certain injectable medications, controlled substances, and drugs subject to a Risk Evaluation and Mitigation Strategy.

This distinction matters because many high-cost specialty medications are biologics, infused drugs, or require complex handling. These are often the most challenging to source through formal importation pathways.

Some private vendors facilitate direct shipments from foreign pharmacies to plan members. The FDA has clarified that its personal-importation policy does not grant a general right to import unapproved prescription drugs and has issued warning letters to companies supporting such practices for employer-sponsored plans.

Employers should not automatically dismiss all international sourcing arrangements. But they must understand how a program actually operates and seek qualified legal and compliance guidance — not rely solely on vendor presentations.

Labeling a medication as the "same drug" is insufficient.

Employers should know the medication's manufacturing location, intended market, dispensing pharmacy, and handling process from pharmacy to member. Who verifies the authenticity of the medication? How are lot numbers tracked? What happens if the medication is recalled? Who monitors storage temperatures? How are adverse events reported? What happens when a shipment is damaged, delayed, or held at the border?

The FDA warns that medications obtained outside the legitimate drug supply chain may not carry the same assurances regarding safety, effectiveness, and quality as products subject to FDA oversight. Counterfeit products may contain incorrect ingredients, improper dosages, or harmful substances.

A credible sourcing partner must provide documentation to answer these questions — not just general assurances.

International sourcing programs may look attractive on paper, but the true measure is how they perform when an employee actually needs medication.

Specialty medications are not standard retail prescriptions. Many treat complex, serious conditions. Missed shipments or delayed refills can have significant consequences.

Programs should offer proactive refill coordination, direct member support, communication with prescribing physicians, and a clear contingency plan if international delivery is delayed. Members must understand that participation is voluntary, how their information is protected, and the process for returning to the traditional pharmacy benefit if needed.

Savings achieved by confusing employees or causing treatment gaps are not sustainable.

International sourcing should not be evaluated in isolation.

The plan must understand how the arrangement interacts with the PBM, TPA, stop-loss carrier, and plan documents. Employers should confirm whether internationally sourced medications are recognized by the stop-loss carrier, how transactions are reported, and whether members receive credit toward deductibles or out-of-pocket limits.

Vendor agreements should address audit rights, data ownership, privacy protections, indemnification, member support, supply disruptions, and responsibility for medication-related issues.

These decisions are part of the employer's broader responsibility for managing the health plan. The Department of Labor emphasizes that ERISA fiduciaries must follow a prudent process when selecting and monitoring plan service providers and evaluate the reasonableness of compensation and potential conflicts of interest. A low acquisition price does not remove the need for a defensible decision-making process.

The most effective programs are highly targeted.

Rather than attempting to transfer all specialty-drug prescriptions overseas, employers should begin by analyzing claims data to identify a select number of medications with substantial international price differences. Each should then be evaluated individually — focusing on situations where the member is clinically stable, refills can be planned well in advance, and the medication can be shipped without introducing unreasonable handling challenges or risks to continuity of care.

Analysis should compare international costs to the employer's net domestic cost after rebates, manufacturer assistance, alternative funding, and other savings. Employers should also consider whether biosimilars, formulary alternatives, site-of-care strategies, or direct manufacturer arrangements could achieve similar results with less complexity.

Sometimes international sourcing will be the best answer. Sometimes it will not. The goal is to introduce competition for claims that might otherwise go unexamined.

Employers should be cautious of anyone presenting international sourcing as the sole solution to specialty-drug spending.

It is one tool within a broader pharmacy strategy that should also consider PBM contract terms, specialty-pharmacy requirements, rebates, acquisition costs, biosimilars, site of care, manufacturer assistance, and alternative funding.

The objective is not to buy every medication from the lowest-cost country, but to obtain the right medication through a safe, compliant, and financially responsible channel.

For the right employer, the right member, and the right medication, international sourcing can produce meaningful savings without compromising care. But employers should not begin by asking, "How cheaply can we buy this medication overseas?" They should begin by asking, "Can we create a defensible, transparent, and member-safe process that lowers the plan's net cost?"

That is a much better question — and it usually leads to a stronger health plan.